SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.50
-0.46 (-0.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close68.96
Open68.96
Bid62.28 x 900
Ask79.45 x 3000
Day's Range67.76 - 69.49
52 Week Range50.71 - 84.37
Volume686,427
Avg. Volume827,600
Market Cap11.05B
Beta (3Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Markit4 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 29. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.68 billion over the last one-month into ETFs that hold SGEN are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
    Zacks6 days ago

    Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

    Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.

  • Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
    Zacks13 days ago

    Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR

    Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.

  • Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?
    Investor's Business Daily14 days ago

    Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?

    Biotech stocks jumped Monday with Nektar Therapeutics, Iovance Therapeutics and Seattle Genetics stocks among the market leaders. All three rose on promising studies in cancer treatment.

  • Reuters14 days ago

    Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

    An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday. Seattle Genetics shares rose 4.3% to $67.84. Responses were similar even among patients with the worst prognosis, including those whose cancer had spread to the liver, patients who had received three or more previous therapies and those who did not respond to treatment with an immuno-oncology drug, such as Merck & Co's Keytruda, researchers reported.

  • Reuters14 days ago

    Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

    An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday. Responses were similar even among patients with the worst prognosis, including those whose cancer had spread to the liver, patients who had received three or more previous therapies and those who did not respond to treatment with an immuno-oncology drug, such as Merck & Co's Keytruda, researchers reported.

  • Benzinga16 days ago

    The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

    Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...

  • American City Business Journals18 days ago

    Revealed: PSBJ inaugural Middle Market Fast 50 list makers

    The companies on this list are a mix of public and private, and had revenue between $25 million and $1 billion in 2018. Together, they brought in $16.6 billion in revenue last year and employed more than 15,250 in the state and nearly 47,000 globally.

  • Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound?
    Zacks23 days ago

    Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound?

    Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Seattle Genetics, Inc. (NASDAQ:SGEN): Financial Strength Analysis
    Simply Wall St.last month

    Seattle Genetics, Inc. (NASDAQ:SGEN): Financial Strength Analysis

    With a market capitalization of US$11b, Seattle Genetics, Inc. (NASDAQ:SGEN) is a large-cap stock, which is considered...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SGEN earnings conference call or presentation 25-Apr-19 8:30pm GMT

    Q1 2019 Seattle Genetics Inc Earnings Call

  • Top Biotech Stocks for February 2019
    Investopedia2 months ago

    Top Biotech Stocks for February 2019

    Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.

  • Seattle Genetics' "Growth Is Tracking Well"
    Motley Fool2 months ago

    Seattle Genetics' "Growth Is Tracking Well"

    The biotech is on track to hit its 2019 revenue guidance for Adceris sales to increase 28% to 34%.

  • Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
    Zacks2 months ago

    Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark

    Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

  • SEATTLE GENETICS INC (SGEN) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    SEATTLE GENETICS INC (SGEN) Q1 2019 Earnings Call Transcript

    SGEN earnings call for the period ending March 31, 2019.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...

  • Associated Press2 months ago

    Seattle Genetics: 1Q Earnings Snapshot

    On a per-share basis, the Bothell, Washington-based company said it had a loss of 8 cents. Losses, adjusted for investment gains, came to 32 cents per share. The results beat Wall Street expectations. ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...

  • Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)?
    Insider Monkey2 months ago

    Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)?

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know

    Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified?
    Simply Wall St.2 months ago

    Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified?

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. To wit, the Seattle Genetics, Inc. (NASDAQ:SGEN...

  • Seattle Genetics' Adcetris Progresses Well Amid Competition
    Zacks2 months ago

    Seattle Genetics' Adcetris Progresses Well Amid Competition

    Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.

  • GuruFocus.com2 months ago

    5 Oncology Companies That Are Set to Run

    The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.